Iterum Therapeutics Plc Share News

DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the U.S. Food and Drug Administration (FDA) has determi...

Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024 Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024

Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey N. Fishman - CEO Judith M.

- -NDA Resubmitted; FDA Action Expected in Early Q4 24-- - -Cash Runway into 2025, including through Potential FDA Approval--

DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its first quarter 2024 financia...

--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024--

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

- -Resubmission of NDA On Track for Early Q2 24— - -Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to t...